Currently, common screening indicators, including PD-L1 (CD274) expression, tumor mutation burden (TMB), and other molecules, such as CD28 and lactate dehydrogenase, are also used to assist in the judgment of immunotherapy efficacy3. The gene discussed is CD274; the disease is neoplasm.